businessfortnight

Shilpa Medicare on Monday said it has received approval from the US health regulator for Gemcitabine for injection, used for treatment of various types of cancers. The approved product is a generic equivalent of reference listed drug Gemzar. The company has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA), Gemcitabine for injection USP in the strengths of 200 mg/vial and 1 g/vial, Shilpa Medicare said in a BSE filing. Gemcitabine for injection USP is used in the treatment of ovarian cancer, breast cancer, non-small cell lung cancer and pancreatic cancer. Shilpa Medicare gets USFDA nod for cancer drug Quoting IQVIA MAT data for December 2018, Shilpa Medicare said, the US market for Gemcitabine for injection USP, 200 mg/vial and 1 g/vlal is approximately USD 11.7 million. Shares of Shilpa Medicare were trading 2.19 percent up at Rs 359 apiece on BSE. source: moneycontrol

New Delhi, 22 February 2019:   MobiKwik , India’s largest digital financial services platform, today announced the launch of digital life insurance on its app to its users. MobiKwik in association with ICICI Prudential Life Insurance Company has rolled out first-of-its-kind group micro insurance product. The offering begins with a life cover of Rs. 1 lakh available for a monthly premium as low as Rs. 20/-. This is the second big announcement by MobiKwik in the digital insurance space, post the launch of accidental insurance in November 2018. MobiKwik offers Instant Life Insurance for Rs 20 on its App  The users have an option to choose from three sum assured policies: Rs 1 lakh, 1.5 lakhs and 2 lakhs, available against monthly premiums of Rs 20/-, 30/- and 40/- respectively. Life insurance can be digitally purchased on the MobiKwik app, via a paperless, 2-step process that takes 10 seconds and the policy is issued instantly. MobiKwik will be extending its base of insurance providers i

New Delhi:  The Indian Railways Catering and Tourism Corporation (IRCTC) has finally opened booking for Train 18 or the Vande Bharat Express. People have been eagerly waiting to travel in India’s fastest train, touted as the new Shatabdi Express. Tickets can be bought over the counter or on irctc.co.in. Train 18, which will run between Delhi and Varanasi, will be flagged off by PM Narendra Modi on 15 February but its commercial run will begin from 17 February. Reservations for Delhi Varanasi Train 18 start: 10 things to know 1. New Delhi-Varanasi Vande Bharat Express will depart from the national capital at 6 am and reach Varanasi at 2 pm. On the same day it will depart from Varanasi at 3pm and reach Delhi at 11 pm. 2. The Vande Bharat Express will operate on five days in a week, except on Monday and Thursday. Vande Bharat (Train 18) train at Varanasi Railway Junction, Photo: PTI 3. From Delhi to Varanasi an air-conditioned chair car ticket will cost  ₹ 1,760 and the executive class

Drug firm Strides Pharma Scienceon Wednesday said it has received the Establishment Inspection Report (EIR) from the US health regulator for its formulations facility in Bangalore. “The company’s formulations facility (KRSG Gardens) in Bangalore which was inspected by the US Food and Drug Administration (USFDA) in August 2018 and November 2018, has received the Establishment Inspection Report (EIR), thereby confirming the successful closure of the inspections,” Strides Pharma Science said in a BSE filing. USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection. The company further noted that the inspection conducted in November 2018 had concluded with zero 483 observations. Strides Pharma Science gets EIR for Bangalore facility As per the USFDA, a Form 483 is issued to a firm’s management at the conclusion of an inspection when investigator has observed any conditions that in its judgment may constitute violations of th